Curocell makes CAR-T cell therapies, in which a patient's own immune cells (T cells) are removed, genetically modified to attack cancer, and then returned to the body; its lead product is 'Limkato injection (anbalcel),' for patients with relapsed or refractory large B-cell lymphoma. On April 29, 2026 it received product approval from the Ministry of Food and Drug Safety, setting a milestone as the first CAR-T developed in-house by a domestic company, and a firm that had zero revenue crossed into the commercialization stage; in the same month of April, a rights offering and convertible-bond issuance secured commercialization funds while also creating the potential for stake dilution. What stands out lately is that it is strong if the approved drug quickly translates into prescriptions and revenue and the secured funds carry it through the loss-making period, but there is still no revenue so earnings power has not been confirmed in numbers, and the new and convertible securities could lead to future stake dilution.
At-a-glance assessment financial health · growth · profitability · valuation
- Debt far exceeds equity (debt ratio 2083.4%).
- Assets that can be turned to cash within a year fall short of near-term liabilities (current ratio 33.3%).
- The most recent full-year net result was a loss.
- ROE is -921.5% (total-net basis). It is below the sector average.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder Kim Gun-soo 10.67% (individual)
Controlling bloc incl. related parties 18.7%
With the controlling bloc holding 19%, control is maintained but the free float is relatively large.
🔎 In-depth analysis
- Curocell makes CAR-T cell therapies, in which a patient's own immune cells (T cells) are removed, genetically modified to attack cancer, and then returned to the body.
- Its lead product is 'Limkato injection (active ingredient anbalcel),' for adult patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) that relapses or responds poorly even after two or more lines of treatment.
- In April 2026 it received product approval from the Ministry of Food and Drug Safety, setting a meaningful milestone as the 'first CAR-T developed in-house by a domestic company.' Revenue was zero through the FY2025 approval period because until then this was a company developing a drug, not one selling products.
- From here it enters an early commercialization phase where, by supplying the approved drug to patients, revenue begins to arise for the first time.
- The latest close is 27,350 won and the market cap is 416.4 billion won.
- The price sits below the 20-day line (30,468 won) and below the 60-day line (40,308 won).
- Trading below both the short-term and medium-term moving averages, the trend is on the depressed side.
- The RSI (a supplementary gauge that compares upward and downward force over the past 14 days on a 0-100 scale) is 37.7, a neutral level.
- The one-month change is -3.2%, the three-month change is -46.5%, and the position relative to the 52-week high is -57.9%.
- Relative strength versus the KOSDAQ is 51 (on a 1-99 scale, converted from returns against the index over the past year with heavier weight on recent performance; higher means stronger than the market).
- That places it in roughly the top 49% by strength among all stocks.
- Over the past three months it lagged the index by 30.6%.
- It is best to read the chart alongside trading volume and disclosure dates.
- On a confirmed annual (FY2025) basis, net profit was a loss, so the P/E (how many times the price is versus one year of earnings) cannot be calculated.
- The P/B (how many times the price is versus the company's net assets) prints high at 82.88x, but this is less a sign that the company is expensive than an illusion arising because cumulative losses have thinned net assets per share (BPS) to 330 won.
- For a drug developer that has spent funds on R&D without revenue, this is a natural picture and is not a metric to be taken on its own as a 'burden.' A negative ROE (how much is earned in a year on equity), a debt ratio (debt versus equity) of 2083%, and a current ratio of 33% are in the same vein - the kind of financial structure often seen at a drug-developing company just before commercialization.
- Rather than reading these past metrics as danger signals, the key is to watch how the funds raised in the just-prior quarter change this structure and whether commercialization revenue actually comes in.
- Revenue was zero in 2023, 2024, and 2025, so a growth rate in the traditional sense does not yet exist.
- Over the same period, operating results showed a steady R&D-cost structure - -31.1 billion won (2023), -36.6 billion won (2024), and -36.3 billion won (2025) - and net losses were -29.6 billion, -38.2 billion, and -46.3 billion won.
- In Q1 2026 as well, revenue was zero, the operating loss was -7.8 billion won, and the net loss was -8.7 billion won.
- These past numbers are costs from the drug-development period, not values that show the company's future earnings power.
- The starting point of growth is the moment Limkato, approved in April 2026, is first booked as quarterly revenue, and since the company has not provided an official numerical outlook, this year's earnings are not asserted in numbers.
- Still, the fact that Korea's first CAR-T passed approval and stands at the starting line of generating revenue is a clear change, and what to track from here is how quickly prescriptions and revenue show up in quarterly results.
- Recent activity centers on two things.
- First, the April 29, 2026 disclosure that the Ministry of Food and Drug Safety approved Limkato (anbalcel), a turning point at which a company with zero revenue crosses into the commercialization stage.
- Second, the rights offering and convertible-bond issuance resolved on April 17 of the same month, which secured the operating funds and production-facility (GMP) funds needed for commercialization while also creating a two-sided effect where the increased share count can dilute existing shareholders' stakes.
- On April 27, the results of that issuance were confirmed by voluntary disclosure.
- In May, an application to change a clinical-trial plan, a stock-option grant to executives and staff, and a large-holding change disclosure followed.
- The key to reading this stock's events is viewing the progress of approval and the dilution from the capital raise together in the same period.
- The strength is that Limkato passed approval as Korea's first CAR-T and revenue has just begun to arise, and that in the just-prior quarter the company pre-emptively secured commercialization and production funds, laying a footing for early operations.
- Actually obtaining a rare new-drug approval is in itself a clear achievement for this company.
- The cautions are that there is still zero revenue so earnings power has not been confirmed in numbers, that capital is thin from cumulative losses, and that the new and convertible securities from the fundraising could lead to future stake dilution.
- In short, this company is strong under conditions where 'the approved drug quickly connects to prescriptions and revenue and it advances by weathering the loss-making period on the secured funds,' and weak in a phase where revenue realization is slow or additional funds become necessary.
- Rather than confirmed results, tracking the progress of commercialization and the first appearance of quarterly revenue is the appropriate way to understand this stock.
🔎 Valuation vs peers Inconclusive
As a pre-revenue, loss-making new-drug developer, an earnings-based comparison is difficult, so only its position was gauged by grouping biotech new-drug developers such as cell and gene therapy makers within the same R&D industry by business substance.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| LigaChem Biosciences | — | 8.62x | -18.04% |
| SK Biopharmaceuticals | 23.53x | 7.73x | 32.83% |
| Alteogen | 113.48x | 36.11x | 31.82% |
Among the peer set, LigaChem Biosciences is likewise at a loss-making stage (ROE -18%), so it is in a similar position to Curocell, while SK Biopharmaceuticals and Alteogen are already profitable with computable P/E ratios, making a like-for-like comparison difficult. For Curocell, (a) there is no earnings-based metric (P/E), and (b) the P/B looks high, but this is a result of thinned capital rather than a premium, so it does not form a basis to declare it 'expensive' or 'cheap.' (c) Last year's confirmed (trailing) results, with zero revenue and a loss, cannot illuminate the future, and the forward value hinges on whether Limkato, approved in April 2026, translates into actual revenue and profit - and no official numerical company outlook has been confirmed. Therefore, valuation at the current stage is left as inconclusive, and it is appropriate to reassess after observing the first appearance and trend of commercialization revenue.
Price history Close · MA20 · MA60
The latest close is ₩27,350 and the market capitalization is ₩416.4 billion. The price sits below its 20-day moving average (₩30,468) and below its 60-day moving average (₩40,308). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 37.7, a neutral level. The one-month change is -3.2%, the three-month change is -46.5%, and the position relative to the 52-week high is -57.9%. Relative strength versus the KOSDAQ is 51 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 51% of all stocks. Over the past three months it lagged the index by 30.6%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -30.61% / 6M -35.05% / 12M -14.34%
Key metrics vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 82.88x is above the sector median (7.05x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
The debt ratio is 2083.4%, so the financial structure is somewhat high.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — |
| Operating profit | -$20.6M | -$24.3M | -$24.1M | — |
| Net profit | -$19.6M | -$25.3M | -$30.7M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating profit | — | — | -$20.6M | -$24.3M | -$24.1M |
| Net profit | — | — | -$19.6M | -$25.3M | -$30.7M |
The three-year revenue trend is 'mixed'. Operating results are in the red, so a swing back to profit matters more than the growth rate here.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- —
Points to watch
- Debt far exceeds equity (debt ratio 2083.4%).
- Assets that can be turned to cash within a year fall short of near-term liabilities (current ratio 33.3%).
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-04-29FilingApproval of CAR-T cell therapy Limkato (anbalcel) by the Ministry of Food and Drug Safety - for relapsed/refractory large B-cell lymphoma (DLBCL, PMBCL), the first in-house-developed CAR-T in KoreaA turning point at which a clinical-stage company with zero revenue enters the commercialization stage. The timing and scale of the first quarterly revenue going forward are the key points to watch. Source
- 2026-04-17FilingResolution on a rights offering - fundraising to secure commercialization operating funds and expand production facilities (GMP)The positive effect of securing commercialization and production resources must be weighed together with the potential for stake dilution from the new-share issuance. Source
- 2026-04-17FilingResolution on a convertible-bond issuance - additional fundraising alongside the rights offeringSecures more operating and facility funds, but a future increase in share count (dilution) upon conversion and an interest burden may accompany it. Source
- 2026-04-27FilingSecurities-issuance results (voluntary disclosure) - confirmation of the issuance results of the fundraising resolved in AprilConfirms that the fundraising was actually completed. The increased scale of shares and convertible securities determines the future degree of dilution. Source
- 2026-05-22UpdateKey management matter relevant to investment decisions - application to change a clinical-trial planA change in the pipeline's clinical progress. As a clue to indication expansion or follow-on development, it needs to be confirmed alongside subsequent disclosures. Source
- 2026-05-14EarningsQuarterly report (2026.03) - Q1 2026 revenue of zero, operating loss of -7.8 billion won, net loss of -8.7 billion wonNo revenue arose even through Q1 right after approval. Whether commercialization revenue is reflected from later quarters needs to be checked. Source
Figure cross-check computed ↔ external
Recent filings
- 2026-06-02OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-28OwnershipOwnership-change filing
- 2026-05-27Disclosure
- 2026-05-22Disclosure
- 2026-05-15OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-14PeriodicQuarterly report
- 2026-05-07OwnershipOwnership-change filing
- 2026-04-29Disclosure
- 2026-04-27Disclosure
- 2026-04-27Disclosure
- 2026-04-17Material-fact report
- 2026-04-17Material-fact report
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.